IVIEW Therapeutics

IVIEW Therapeutics, Inc.

4 Investors
Clinical-stage biotechnology in ophthalmology
Cranbury, NJ

IVIEW Therapeutics Inc. is a clinical-stage biotechnology company dedicated to developing innovative treatments for ocular diseases. By focusing on unmet medical needs in the ophthalmology sector, the company aims to create effective therapies for conditions including dry eye disease, conjunctivitis, myopia, glaucoma, and presbyopia.

Products & Team

IVW-1001

Ocular treatmentSeed

IVW-1001 is a novel TRPM8 agonist specifically designed for the treatment of dry eye disease. This innovative product is delivered via an ophthalmic eyelid wipe, ensuring both ease of use and targeted action directly at the affected area.

Value Proposition

IVW-1001 addresses the significant quality of life issues faced by patients suffering from dry eye disease, providing a differentiated treatment option with its innovative delivery method.

Pain Points

The company addresses critical patient needs for effective and accessible treatment options for debilitating ocular diseases.

Novel TRPM8 agonist mechanism of actionUnique ophthalmic eyelid wipe delivery systemPositive results from Phase 1/2 clinical trials regarding safety and efficacy

Bo Liang

Company Signatory
Chief Executive Officerat IVIEW Therapeutics, Inc.
Joined IVIEW Therapeutics, Inc.
February 2025

Xiaolu Sun

Directorat IVIEW Therapeutics, Inc.
Joined IVIEW Therapeutics, Inc.
February 2025
Industry
Biotechnology
Primary business sector
Founded
2025
Year established
Location
Cranbury, NJ
Primary headquarters

Funding History

Total Raised:
$7.7M
E

Equity Offering

May 2024
$15.0M
Target
Progress
51%
Raised
$7.7M
Target
$15.0M
#000184874925000001